Prostate monitoring for patients on testosterone replacement therapy, according to age
| Age (years) | Endocrine Society Guidelines5 |
|---|---|
| < 40 | No need for prostate monitoring |
| 40–54 | Baseline prostate-specific antigen and digital rectal examination if high risk,a repeat at 3 to 12 months after starting testosterone replacement therapy, then continue according to screening guidelines |
| 55–69 | Baseline prostate-specific antigen and digital rectal examination, repeat at 3 to 12 months after starting testosterone replacement therapy, then continue according to screening guidelines |
| ≥ 70 | No need for prostate monitoring |
↵a High-risk patients include African Americans and patients with a first-degree relative with confirmed prostate cancer.